Related references
Note: Only part of the references are listed.HSR22-153: Real-World Time to Discontinuation of First-Line Venetoclax + Obinutuzumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Xiaoxiao Lu et al.
Journal of the National Comprehensive Cancer Network (2022)
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
Paul M. Barr et al.
BLOOD ADVANCES (2022)
Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy
Jennifer A. Woyach et al.
BLOOD (2021)
Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia
Jing-Zhou Hou et al.
FUTURE ONCOLOGY (2021)
Outcomes in chronic lymphocytic leukemia patients on novel agents in the US Veterans Health Administration System
Christopher R. Frei et al.
LEUKEMIA & LYMPHOMA (2021)
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)
Pau Abrisqueta et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)
Overall survival benefit of symptom monitoring in real-world patients with chronic lymphocytic leukaemia treated with ibrutinib: a FiLO group study
Loic Ysebaert et al.
EUROPEAN JOURNAL OF CANCER (2020)
Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL
Inhye E. Ahn et al.
BLOOD (2019)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
UK CLL Forum 5 Year Update on 315 Relapsed Refractory CLL Patients Treated with Ibrutinib in 66 UK and Ireland Centres
George A. Follows
BLOOD (2019)
Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience
AnnaLynn M. Williams et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort
Maria Winqvist et al.
HAEMATOLOGICA (2019)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Carol Moreno et al.
LANCET ONCOLOGY (2019)
Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL)
Othman S. Akhtar et al.
LEUKEMIA & LYMPHOMA (2019)
Comorbidities Predict Inferior Outcomes in Chronic Lymphocytic Leukemia Treated With Ibrutinib
Max J. Gordon et al.
CANCER (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study
Anthony R. Mato et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Long-Term Outcomes for Patients With Chronic Lymphocytic Leukemia Who Discontinue Ibrutinib
Preetesh Jain et al.
CANCER (2017)
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
Paul M. Barr et al.
BLOOD (2017)
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
Maria Winqvist et al.
HAEMATOLOGICA (2016)
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
HAEMATOLOGICA (2016)
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
Maria Winqvist et al.
HAEMATOLOGICA (2016)
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
HAEMATOLOGICA (2016)
Share Paper
